---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-019219"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T01:57:48.257980+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allarity enrolls first patient in Phase 2 stenoparib trial for advanced ovarian cancer

## Summary
- First patient dosed in new Phase 2 protocol for platinum-resistant or platinum-ineligible advanced ovarian cancer.
- Trial includes DRP companion diagnostic to enrich for stenoparib responders.
- Two patients remain on prior Phase 2 study on twice-daily dosing, deriving benefit beyond 20 months.
- Additional dosing level added aligning with FDA Project Optimus to inform pivotal trial design.
- Company expects significant clinical data by late summer 2026; pursuing accelerated regulatory pathways.

## SEC filing metadata
- accession: 0001437749-25-019219
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774925019219/0001437749-25-019219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774925019219/allr20250602_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-019219
- JSON: https://secwatch.observer/filing/0001437749-25-019219.json
- Plain text: https://secwatch.observer/filing/0001437749-25-019219.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.